Pharmaceutical Technology
OCTOBER 5, 2022
In 2009, former Biogen employee Michael Bawduniak filed a lawsuit claiming that Biogen had violated the False Claims Act and the Anti-Kickback Statute by providing millions of dollars to healthcare providers (HCPs) as an incentive to prescribe three of its multiple sclerosis (MS) drugs.
PM360
JUNE 29, 2022
However, the good news is that patients are asking their doctors for help—76% of surveyed patients reported having talked with their healthcare providers about migraine treatment options, and within that group, 64% and 54% discussed acute medications and preventive treatments, respectively.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
JULY 20, 2023
Overall, while the proposed regulation on SoHO may present some challenges for ATMP developers, it is also expected to ultimately improve patient safety and thus build trust not only in ATMPs, but also among patients and healthcare providers, which could ultimately benefit ATMP developers in the long run. Cited 2023Mar].
Cadensee
JULY 20, 2021
02:25 Uri Goren talks about his road to become a trailblazer and advocate for patient-centric healthcare. 52:21 Uri's opinion about the main problem that needs to be solved for the healthcare market with technology. When he was going through his cancer, he died in 2004. Interview Transcription (mild edits).
Pharmaceutical Technology
JANUARY 6, 2023
In 2020, the Federal Trade Commission issued a report regarding settlements reached between brand and generic manufacturers in FY 2017 and noted that “for the first time since [FY] 2004, no settlement agreement in [FY] 2017 contains a no-[authorized generic] AG commitment.”. Throughout 2022, Novartis was at the opposing ends of legal cases.
Expert insights. Personalized for you.
59 
Let's personalize your content